Bleeding Disorders: Insights into Aetiology, Pathogenesis, Diagnosis and Management

Ahmed M Kabel^{1, 2,}

¹Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

²Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

Cite this paper:
Ahmed M Kabel. Bleeding Disorders: Insights into Aetiology, Pathogenesis, Diagnosis and Management. International Journal of Hematological Disorders. 2014; 1(1):22-26. doi: 10.12691/ijhd-1-1-4

Abstract

Background: Coagulation plays an important role in haemostasis. Bleeding disorders caused by deficiency of certain coagulation factors such as hemophilia and Von Willebrand disease can affect haemostasis and may endanger life. Aim: To put a focus on the aetiology, pathogenesis, methods of diagnosis and lines of management of bleeding disorders. Conclusion: Bleeding disorders usually result from hereditary deficiency of certain coagulation factors. These disorders often affect lifestyle of the patient and may have serious complications. Further studies are needed to explore the exact pathogenesis of these disorders and new lines of management especially for gene therapy.

Keywords:
hemophilia pathogenesis diagnosis management

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Parker CS, Tsai J, Siddiqi AE, Atrash HK, Richardson LC (2014): Meeting the Emerging Public Health Needs of Persons With Blood Disorders. Am J Prev Med; pii: S0749-3797 (14)00374-2.
[2]	Michelson AD (2012): Platelets. Academic Press. pp. 3-5.
[3]	Hayward CP (2005): Diagnosis and management of mild bleeding disorders. Hematology Am Soc Hematol Educ Program. 423-8.
[4]	Venkateswaran L, Wilimas JA, Jones DJ, Nuss R (2004): Mild hemophilia in children: prevalence, complications, and treatment. J Pediatr Hematol Oncol; 20 (1): 32-5.
[5]	Sona PS, Muthu LC (2010): Hemophilia-an overview. Int J Pharmaceut Sci Rev Res; 5 (1): 18-26.
[6]	Peretz H, Butler R (2004): A common ancestral mutation (C128X) occurring in 11 non-Jewish families from the UK with factor XI deficiency. J Thromb Haemost; 2 (6): 918-24.
[7]	Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD (2009): Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost; 7: 1418-21.
[8]	Jones DJ, Venkateswaran L, Wilimas JA, Nuss R (2009): Mild hemophilia in children: prevalence, complications, and treatment. J Pediatr Hematol Oncol; 20 (1): 32-5.
[9]	Salomon O, Steinberg DM, Morag N, Tanne D (2008): Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood; 111 (8): 4113-7.
[10]	Udvardy ML, Szekeres-Csiki K, Hársfalvi J (2009): Evaluation method for densitometric curves of von Willebrand factor multimers and a new parameter to describe the degree of multimersation. Thromb Haemost; 102 (2): 412-7.
[11]	Goodeve A, Eikenboom J, Castaman G, Rodeghiero F (2007): Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood; 109: 112-121.
[12]	Sutherland MS, Cumming AM, Bowman M (2009): A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood; 114 (5): 1091-8.
[13]	Mancuso ME, Santagostino E, Tripodi A (2010): Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost; 8: 737.
[14]	Gomez K, Bolton-Maggs P (2008): Factor XI deficiency. Haemophilia; 14 (6): 1183-9.
[15]	Berntorp E, Shapiro AD (2012): Modern haemophilia care. Lancet; 379: 1447-56.
[16]	Chitlur M, Warrier I, Rajpurkar M, Lusher JM (2009): Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia; 15: 1027-31.
[17]	Astermark J (2006): Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia;12 (Suppl 6): 8-13; discussion 13-14.
[18]	Hay CR, Brown S, Collins PW, Keeling DM, Liesner R (2006): The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol; 133: 591-605.
[19]	Oldenburg J, Pavlova A (2006): Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia; 12 (Suppl 6): 15-22.
[20]	Miller CH, Benson J, Ellingsen D et al. (2012): F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia; 18: 375-82.
[21]	Astermark J, Oldenburg J, Carlson J et al. (2006): Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood; 108: 3739-45.
[22]	Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK (2007): Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost; 5: 263-5.
[23]	Gouw SC, van der Bom JG, Ljung R et al. (2013): Factor VIII Products and Inhibitor Development in Severe Hemophilia A. N Engl J Med; 368: 231-9.
[24]	Gouw SC, van der Bom JG, van den Berg HM (2007): Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood; 109: 4648-54.
[25]	Astermark J, Donfield SM, Gomperts ED et al. (2013): The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood; 121: 1446-54.
[26]	Cutler J, Chappell LC, Kyle P, Madan B (2013). Third trimester amniocentesis for diagnosis of inherited bleeding disorders prior to delivery. Haemophilia; 19: 904.
[27]	Richards M, Lavigne LG, Combescure C, et al. (2012): Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol; 156: 374.
[28]	Biss TT, Blanchette VS, Clark DS, Bowman M, Wakefield CD, Silva M, Lillicrap D, James PD, Rand ML (2010): Quantitation of bleeding symptoms in children with heamophilic Disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost; 8: 950-6.
[29]	Kessler C (2007): Hemorrhagic disorders: Coagulation factor deficiencies. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier: Chap 180.
[30]	Ragni MV, Lusher JM, Koerper MA (2006): Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. Haemophilia; 6:98.
[31]	Jansen NW, Roosendaal G, Lafeber FP (2008): Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol; 143:632.
[32]	Coller BS, Schneiderman P (2005). Clinical evaluation of hemorrhagic disorders: the bleeding history and differential diagnosis of purpura. In Hematology. Basic Principles and Practice. Philadelphia: Elsevier Churchill Livingstone; pp. 1975-99.
[33]	Tsoukas C, Eyster ME, Shingo S (2006): Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood; 107 (5): 1785-90.
[34]	Colvin BT, Astermark J, Fischer K, Gringeri A, Lassila R, Schramm W, Thomas A, Ingerslev J (2008): Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia; 14 (2): 361-74.
[35]	Franchini M, Targher G, Montagnana M, Lippi G (2009): Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery,J Thromb Thrombolysis; 28 (2): 215-9.
[36]	Friedman M, White B, Dougall AJ (2009): An audit of the protocol for the management of patients with hereditary bleeding disorders undergoing dental treatment. J Disab Oral Health; 10 (4): 151-55.
[37]	Gourlay DL, Heit HA, Almahrezi A (2005): Universal precautions in pain medicine: arational approach to the treatment ofchronic pain. Pain Med; 6: 107-12.
[38]	Holstein K, Klamroth R, Perez R, Richards M, Gringeri A (2010): European Survey on PainManagement in Patients with Hemophilia.Presented at: International Congress of the World Federation of Hemophilia; Buenos Aires, Argentina. Haemophilia; 16 (4): 23.
[39]	Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J (2004): Home management of haemophilia. Haemophilia; 10 (2): 118-33
[40]	Hough C, Lillicrap D (2005): Gene therapy for hemophilia: an imperative to succeed. J Thromb Haemost; 3: 1195.
[41]	Chuah MK, Collen D, Vanden Driessche TI (2005): Gene therapy for hemophilia. J Gene Med; 3 (1): 3-20.
[42]	Ohmori T, Mizukami H, Madoiwa S, Ozawa K, Sakata Y (2014): Recent advance in hemophilia therapy (2): gene and celltherapy for hemophilia. Rinsho Ketsueki; 55 (8): 899-907.